China National Accord Medicines Corp Ltd - Asset Resilience Ratio
China National Accord Medicines Corp Ltd (200028) has an Asset Resilience Ratio of -1.21% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check China National Accord Medicines Corp Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1992–2023)
This chart shows how China National Accord Medicines Corp Ltd's Asset Resilience Ratio has changed over time. See China National Accord Medicines Corp Ltd (200028) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down China National Accord Medicines Corp Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of China National Accord Medicines Corp Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | HK$0.00 | 0% |
| Short-term Investments | HK$-621.65 Million | -1.21% |
| Total Liquid Assets | HK$-621.65 Million | -1.21% |
Asset Resilience Insights
- Limited Liquidity: China National Accord Medicines Corp Ltd maintains only -1.21% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
China National Accord Medicines Corp Ltd Industry Peers by Asset Resilience Ratio
Compare China National Accord Medicines Corp Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
China National Medicines Corp Ltd
SHG:600511 |
Medical Distribution | 0.04% |
|
Sigma Healthcare Ltd
AU:SIG |
Medical Distribution | 0.03% |
|
Ebos Group Ltd
AU:EBO |
Medical Distribution | 0.00% |
|
Paragon Care Ltd
AU:PGC |
Medical Distribution | 0.00% |
|
Mayne Pharma Group Ltd
AU:MYX |
Medical Distribution | 4.00% |
|
Cyclopharm Ltd
AU:CYC |
Medical Distribution | 1.98% |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3 |
Medical Distribution | 4.48% |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607 |
Medical Distribution | 4.21% |
Annual Asset Resilience Ratio for China National Accord Medicines Corp Ltd (1992–2023)
The table below shows the annual Asset Resilience Ratio data for China National Accord Medicines Corp Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -1.34% | HK$-639.06 Million ≈ $-81.58 Million |
HK$47.57 Billion ≈ $6.07 Billion |
-1.34pp |
| 2022-12-31 | 0.00% | HK$2.00 ≈ $0.26 |
HK$42.62 Billion ≈ $5.44 Billion |
+1.75pp |
| 2021-12-31 | -1.75% | HK$-747.96 Million ≈ $-95.48 Million |
HK$42.78 Billion ≈ $5.46 Billion |
-0.27pp |
| 2020-12-31 | -1.48% | HK$-585.15 Million ≈ $-74.70 Million |
HK$39.59 Billion ≈ $5.05 Billion |
+0.03pp |
| 2019-12-31 | -1.51% | HK$-505.36 Million ≈ $-64.51 Million |
HK$33.52 Billion ≈ $4.28 Billion |
+0.07pp |
| 2018-12-31 | -1.58% | HK$-456.22 Million ≈ $-58.24 Million |
HK$28.93 Billion ≈ $3.69 Billion |
+0.24pp |
| 2017-12-31 | -1.82% | HK$-405.93 Million ≈ $-51.82 Million |
HK$22.34 Billion ≈ $2.85 Billion |
-0.15pp |
| 2016-12-31 | -1.67% | HK$-355.09 Million ≈ $-45.33 Million |
HK$21.31 Billion ≈ $2.72 Billion |
-0.26pp |
| 2015-12-31 | -1.40% | HK$-185.57 Million ≈ $-23.69 Million |
HK$13.22 Billion ≈ $1.69 Billion |
-0.52pp |
| 2014-12-31 | -0.88% | HK$-112.99 Million ≈ $-14.42 Million |
HK$12.83 Billion ≈ $1.64 Billion |
+0.14pp |
| 2013-12-31 | -1.02% | HK$-113.26 Million ≈ $-14.46 Million |
HK$11.06 Billion ≈ $1.41 Billion |
+0.14pp |
| 2012-12-31 | -1.16% | HK$-108.06 Million ≈ $-13.79 Million |
HK$9.30 Billion ≈ $1.19 Billion |
+0.22pp |
| 2011-12-31 | -1.39% | HK$-106.27 Million ≈ $-13.57 Million |
HK$7.67 Billion ≈ $978.56 Million |
+0.31pp |
| 2010-12-31 | -1.70% | HK$-107.10 Million ≈ $-13.67 Million |
HK$6.31 Billion ≈ $805.09 Million |
-0.46pp |
| 2009-12-31 | -1.24% | HK$-64.69 Million ≈ $-8.26 Million |
HK$5.23 Billion ≈ $668.08 Million |
-0.17pp |
| 2008-12-31 | -1.07% | HK$-39.26 Million ≈ $-5.01 Million |
HK$3.68 Billion ≈ $470.27 Million |
+0.65pp |
| 2007-12-31 | -1.71% | HK$-49.72 Million ≈ $-6.35 Million |
HK$2.91 Billion ≈ $370.97 Million |
-2.06pp |
| 2006-12-31 | 0.35% | HK$9.42 Million ≈ $1.20 Million |
HK$2.68 Billion ≈ $342.02 Million |
+0.35pp |
| 2003-12-31 | 0.00% | HK$4.08K ≈ $520.83 |
HK$1.01 Billion ≈ $128.72 Million |
+0.00pp |
| 2002-12-31 | 0.00% | HK$4.08K ≈ $520.83 |
HK$1.05 Billion ≈ $134.37 Million |
0.00pp |
| 2001-12-31 | 0.00% | HK$4.68K ≈ $597.42 |
HK$1.12 Billion ≈ $142.74 Million |
-6.38pp |
| 2000-12-31 | 6.38% | HK$31.30 Million ≈ $4.00 Million |
HK$490.89 Million ≈ $62.66 Million |
+6.38pp |
| 1997-12-31 | 0.00% | HK$2.00K ≈ $255.31 |
HK$495.82 Million ≈ $63.29 Million |
-0.02pp |
| 1996-12-31 | 0.02% | HK$89.01K ≈ $11.36K |
HK$446.60 Million ≈ $57.01 Million |
0.00pp |
| 1995-12-31 | 0.02% | HK$89.01K ≈ $11.36K |
HK$380.21 Million ≈ $48.53 Million |
+0.00pp |
| 1994-12-31 | 0.02% | HK$88.51K ≈ $11.30K |
HK$379.76 Million ≈ $48.48 Million |
-2.53pp |
| 1993-12-31 | 2.55% | HK$9.80 Million ≈ $1.25 Million |
HK$384.07 Million ≈ $49.03 Million |
+2.50pp |
| 1992-12-31 | 0.05% | HK$97.26K ≈ $12.42K |
HK$188.93 Million ≈ $24.12 Million |
-- |
About China National Accord Medicines Corp Ltd
China National Accord Medicines Corporation Ltd. engages in the retail and distribution of pharmaceutical products in China and internationally. The company offers new and special drugs and medications for chronic diseases. It also provides traditional Chinese medicine, Western medicine, rehabilitation therapy, and various medical-related resources, as well as chemical drugs, OTC drugs, and healt… Read more